Свяжитесь с нами

RU

Главная > Поддержка > Заказ литературы

Evolution of myeloid-mediated immunotherapy resistance in prostate cancer

10.1038/s41586-024-08290-3

Affiliations
Aram Lyu, Zenghua Fan, Matthew Clark, Averey Lea, Diamond Luong, Ali Setayesh, Alec Starzinski, Rachel Wolters, Marcel Arias-Badia, Kate Allaire, Kai Wu, Vibha Gurunathan, Laura Valderrábano, Xiao X Wei, Richard A Miller, Eliezer M Van Allen, Lawrence Fong

DOI: 10.1038/s41586-024-08290-3

Abstract
Patients with advanced metastatic castration-resistant prostate cancer (mCRPC) are refractory to immune checkpoint inhibitors (ICIs)

Keywords
mCRPC，CD3，ICIs

Связанные продукты

Каталожный номер	Название продукта	Описание	Цель
HY057507	CD3	Anti-Human CD3 epsilon Recombinant Antibody (SP34) (HY057507) is a mouse monoclonal antibody detecting CD3 epsilon in FCM. Suitable for Human. Highlights ●Affinity Purified — Minimal background and high purity for reliable results.	CD3E, CD3e, T-cell surface antigen T3/Leu-4 epsilon chain, T-cell surface glycoprotein CD3 epsilon chain, T3E